Results 311 to 320 of about 5,323,640 (377)

Optimizing saffron bioactive extraction with deep eutectic solvents. [PDF]

Sci Rep
Saberi A, Raissi H, Zaboli A, Hashemzadeh H.   +3 more
europepmc   +1 more source

Ubiquitination of transcription factors in cancer: unveiling therapeutic potential

Molecular Oncology, EarlyView.
In cancer, dysregulated ubiquitination of transcription factors contributes to the uncontrolled growth and survival characteristics of tumors. Tumor suppressors are degraded by aberrant ubiquitination, or oncogenic transcription factors gain stability through ubiquitination, thereby promoting tumorigenesis.
Dongha Kim, Hye Jin Nam, Sung Hee Baek
wiley   +1 more source

Interplay of protection and damage through intermolecular processes in the decay of electronic core holes in microsolvated organic molecules.

Phys Chem Chem Phys
Bloß D, Kryzhevoi NV, Maurmann J, Schmidt P, Knie A, Viehmann JH, Küstner-Wetekam C, Deinert S, Hartmann G, Trinter F, Cederbaum LS, Ehresmann A, Kuleff AI, Hans A.   +13 more
europepmc   +1 more source

Structural and Electronic Properties of Thiophene-Based Supramolecular Architectures: Influence of the Underlying Metal Surfaces. [PDF]

Nanomaterials (Basel)
Kang L, Tian Y, Lu H, Xia S, Xu X, Yang Z.   +5 more
europepmc   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

The Emergence of Nanofluidics for Single-Biomolecule Manipulation and Sensing. [PDF]

Anal Chem
Iarossi M, Verma NC, Bhattacharya I, Meller A.   +3 more
europepmc   +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

Molecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu   +12 more
wiley   +1 more source

Design and computational screening of high-energy, low-sensitivity bistetrazole-based energetic molecules. [PDF]

RSC Adv
Cheng P, Jin Y, Wang D, Tao S.
europepmc   +1 more source

Does Porphyromonas gingivalis truly inhibit the oral carcinogenesis?

Molecular Oncology, EarlyView.
 
Chen‐xi Li, Zhong‐cheng Gong
wiley   +1 more source

Generating diversity and securing completeness in algorithmic retrosynthesis. [PDF]

J Cheminform
Mrugalla F, Franz C, Alber Y, Mogk G, Villalba M, Mrziglod T, Schewior K.   +6 more
europepmc   +1 more source